Thrombectomy is the focus this week, with two major announcements that could meaningfully move this space forward. One came from Inquis Medical, which announced a $75 million Series C round backed by an undisclosed strategic investor. The other came from Boston Scientific, which announced plans to acquire Penumbra for $14.5 billion, marking the largest acquisition in Boston Scientific’s history.
Together, these headlines point to a market where mechanical clot removal is gaining momentum across multiple indications. The thrombectomy devices market remains underpenetrated in several of its largest patient populations, which is helping drive both investment and M&A activity.
Thrombectomy refers to the surgical removal of a thrombus, or blood clot. The procedure is a minimally invasive surgery that uses a catheter-based device to mechanically fragment, retrieve, or aspirate clot material to restore blood flow.
The procedure is often used when rapid reperfusion is critical, including:
In select cases, thrombectomy is also performed in coronary arteries to clear occluded vessels.
Thrombectomy is relevant across several thrombus-related conditions:
Inquis Medical is a privately held, commercial-stage company focused on PE intervention. Its flagship product, the AVENTUS™ Thrombectomy System, is intended for PE treatment and incorporates two differentiating features:
The Series C financing is intended to help Inquis scale commercial operations following FDA 510(k) clearance for AVENTUS in June 2025.
The size of the round and the presence of a single unnamed strategic investor make the deal unusual. Boston Scientific initially seemed like a plausible candidate, given its acquisition pace, but the Penumbra announcement later in the week complicates that assumption.
Other possible strategics discussed include Medtronic, which competes across thrombectomy segments and has a history of large strategic investments, and Terumo, which has an established vascular strategy and active VC presence.
Stryker appears less likely, given its acquisition of Inari Medical for $4.9 billion last year and limited evidence of strategic minority investments.
Boston Scientific’s announced acquisition of Penumbra follows its earlier announcement that it is acquiring Valencia Technologies. The Penumbra deal brings Boston Scientific’s acquisition count to six year-to-date and 10 over the past two years.
Boston Scientific has built an estimated $200 million thrombectomy business around AngioJet™ and EKOS™, though some analysts suggest these assets may need to be divested for the transaction to proceed.
Penumbra reported early FY25 results showing annual revenue growth of roughly 17% compared to FY24. In 2024, Penumbra’s thrombectomy business grew approximately 20% compared to 2023.
Penumbra is widely considered a market leader in thrombectomy, and Boston Scientific will now own that position.
This was a major week for thrombectomy, with strategic investment flowing into Inquis Medical and Boston Scientific announcing its largest acquisition ever with Penumbra. Across stroke, PE, and other clot-related indications, thrombectomy remains a large, underpenetrated opportunity, and these two deals reflect growing confidence in the long-term trajectory of the thrombectomy devices market.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy